Subscribe To
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction No induced metabolism of palbociclib and no safety interaction was observed Overall tolerability profile of the combination consistent with the FDA-approved label of palbociclib plus an endocrine agent Phase 2 dose expansion of […] The post Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 In...
Read More
Content Topics
Olema
Oncology
Announces
Op
1250
Demonstrates
Attractive
Op 1250
Combinability
Inhibitor
Palbociclib
Escalation
Forex
Posted: Dec 7 2022, 20:37
Author Name: forextv
Views: 101831